The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
TCT 2021 | Transplantation in MF: patient-centered communication and decision making
Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, explores transplant decision-making for patients with myeloproliferative neoplasms, highlighting the potential of transplant-related complications as well as ensuring that patients are highly informed when making the decision to proceed with transplantation. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.
